pipeline

robust, late-stage neuroscience pipeline

Sunosi AXS-05 Alzheimer’s Disease Agitation: Breakthrough Therapy Designation Smoking Cessation AXS-07 Migraine AXS-12 Narcolepsy: Orphan Therapy Designation AXS-14 Fibromyalgia

Abbreviations: MOA = Mechanism of Action; NMDA = N-Methyl-D-aspartate; COX-2 = Cyclooxygenase-2; 5-HT = 5-Hydroxytryptamine; NE = Norepinephrine; TAAR1 = Trace amine-associated receptor 1

The products and/or investigational product candidates listed on this page are not approved by the FDA or have not been approved for the above-referenced indications, and the safety and effectiveness of such has not been established.